Los Angeles, CA, United States of America

Mary Faris

This inventor holds 104 USPTO granted patents and 17 published patent applications, plus 9 CIPO patents and 13 EPO patents, primarily in Cancer Therapeutics (CPC class A61K2039-505). Top assignees: Agensys, Inc., Mannkind Corporation, Tolero Pharmaceuticals, Inc.. Active years: 2003-2022.

USPTO Granted Patents = 104 (Patent Applications = 17)

% Patents Active = 32.7

CIPO Patents = 9 (Patent Applications = 3)

EPO Patents = 13 (Patent Applications = 11)

Average Co-Inventor Count = 6.6

ph-index = 14

Forward Citations = 594(Granted Patents)

Forward Citations (Not Self Cited) = 552(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Tolero Pharmaceuticals, Inc.

Incyte Genomics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2003-2022

Loading Chart...

Areas of Expertise:

Antibodies

Nucleic Acids

Kinase Inhibitors

STEAP-1 Proteins

Cancer Detection

Tumor Diagnosis

Immune Response

Transmembrane Antigens

Cancer Treatment

Bladder Cancer

Prostate Cancer

Molecular Inhibitors

104 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11401347 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2022-08-02),

2. 10597463 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2020-03-24),

3. 9714247 - Multiple kinase pathway inhibitors (2017-07-25),

4. 9617346 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2017-04-11),

5. 9493454 - Multiple kinase pathway inhibitors (2016-11-15),

6. 9029516 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2015-05-12),

7. 9023605 - Antibodies and molecules derived therefrom that bind to STEAP-1 proteins (2015-05-05),

8. 8951744 - Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers (2015-02-10),

9. 8945570 - Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers (2015-02-03),

10. 8846043 - Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer (2014-09-30),

11. 8647826 - Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer (2014-02-11),

12. 8604169 - Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer (2013-12-10),

13. 8604031 - Intracellular kinase inhibitors (2013-12-10),

14. 8562989 - Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer (2013-10-22),

15. 8497351 - Nucleic acid and corresponding protein entitled 162P1E6 useful in treatment and detection of cancer (2013-07-30),

Title: Mary Faris: Inspiring Generations with Innovation

Introduction:

Mary Faris, a prolific inventor based in Los Angeles, CA, is a trailblazer whose creativity, passion, and dedication have shaped groundbreaking inventions. With over 104 patents to her name, Mary Faris continues to inspire future inventors with her commitment to making the world a better place through her innovative creations.

Latest Patents:

Among her latest patents is the development of antibodies and molecules that target the STEAP-1 protein. These inventions have significant implications for cancer diagnosis, prognosis, prevention, and treatment. STEAP-1, which shows specific expression patterns in normal adult tissue and in certain cancers, serves as a valuable target for therapeutic interventions aimed at combating cancer.

Career Highlights:

Throughout her illustrious career, Mary Faris has made significant contributions to the fields of biotechnology and healthcare. She has worked with renowned companies such as Agensys, Inc. and Mannkind Corporation, where her innovative spirit and dedication to discovery have led to groundbreaking advancements in medical science.

Collaborations:

Mary Faris has collaborated with esteemed colleagues, including Arthur B Raitano and Aya Jakobovits, who have played pivotal roles in translating her inventive ideas into tangible solutions. Through these collaborations, Mary Faris has fostered a culture of innovation and teamwork, setting new standards for excellence in the industry.

Conclusion:

In conclusion, Mary Faris stands as a beacon of inspiration for aspiring inventors, showcasing the transformative power of creativity and dedication in driving meaningful change. Her pioneering work in the realm of biotechnology and healthcare continues to leave a lasting impact, shaping the future of innovation and improving the lives of many. Mary Faris's legacy serves as a reminder of the endless possibilities that lie ahead for those who dare to dream and innovate.